A Trenton federal judge has dismissed a False Claims Act suit against Sanofi and Bristol-Myers Squibb over anti-blood clot drug Plavix, citing a change in the composition of the partnership that filed the suit.

The defendants in United States, ex rel. JKJ Partnership 2011 v. Sanofi Aventis U.S., filed in October 2011, are accused of failing to disclose that about 30 percent of the general public was genetically disposed to show diminished or no response to Plavix, including many African-Americans and Asian-Americans. The suit was filed by JKJ Partnership 2011, and became part of the consolidated litigation over Plavix, which is ongoing.